Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesWages, Salaries and Other
Ratios

Amphastar Pharmaceuticals (AMPH) Leases (2016 - 2025)

Historic Leases for Amphastar Pharmaceuticals (AMPH) over the last 13 years, with Q3 2025 value amounting to $44.6 million.

  • Amphastar Pharmaceuticals' Leases rose 4058.6% to $44.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.6 million, marking a year-over-year increase of 4058.6%. This contributed to the annual value of $46.9 million for FY2024, which is 4504.99% up from last year.
  • Per Amphastar Pharmaceuticals' latest filing, its Leases stood at $44.6 million for Q3 2025, which was up 4058.6% from $44.2 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Leases peaked at $46.9 million during Q4 2024, and registered a low of $19.3 million during Q1 2021.
  • For the 5-year period, Amphastar Pharmaceuticals' Leases averaged around $31.7 million, with its median value being $27.8 million (2022).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Leases soared by 5901.32% in 2021, and later crashed by 733.4% in 2023.
  • Over the past 5 years, Amphastar Pharmaceuticals' Leases (Quarter) stood at $26.9 million in 2021, then decreased by 4.98% to $25.6 million in 2022, then increased by 26.53% to $32.3 million in 2023, then surged by 45.05% to $46.9 million in 2024, then decreased by 4.95% to $44.6 million in 2025.
  • Its Leases stands at $44.6 million for Q3 2025, versus $44.2 million for Q2 2025 and $45.8 million for Q1 2025.